Osiris Therapeutics Inc. (OSIR)

[tedkov]

Osiris Shareholders Upset Over Merger Bid - (via Business Journal)
March 12, 2019
Tags: NewsPoints Osiris Smith & Nephew United States Corporate Affairs Mergers &
Acquisitions

A group of Osiris Therapeutics Inc. shareholders are attempting
to block the $660.5 million purchase of the company by Smith & Nephew plc.

The shareholders allege that the purchase price of $19 per share is insufficient in light of the company's growth prospects, and that deal-protection clauses in the merger agreement preclude other
companies from submitting successful competing offers. In addition, shareholders allege that Osiris senior management obtained personal benefits for their own self interests in agreeing to sell the company that are not being shared with common stockholders.

Osiris Therapeutics did not immediately respond to requests for a comment.
To contact the law firm on behalf of shareholders of
Osiris Therapeutics for more information as to how you can participate with other shareholders for a higher price at no cost or expense call toll free 800.511.7037 or [e-mail]

[spsiege]

The Street raised OSIR to Buy with a target of $19.10

[Renee]

OSIR moved from the OTC to the Nasdaq:

http://otce.finra.org/DLDeletions

[sabadollar]

Next week will be the last chance to buy under 10$! Will buy more on Monday ??

[Logon26]

Bye Bye OTC - 10-K out

[Logon26]

The Company currently expects that it will file the comprehensive Form 10-K filing no later than March 28, 2018.

[sabadollar]

Osir buy 8,6 - expecting financials this or next week! $MESO - share price up! also good for OSIR.

[stocktrademan]

OSIR buy 5.720

bull flag
inverted head and shoulders bottom
bullish divergence
support at moving averages
previous high volume indicates the bottom and major support
because most of all the potential sellers are now exhausted and out
price now beginning a nascent uptrend above the ichimoku span clouds

















normal chart




log chart

[Renee]

OSIR: SEC charges Biotech Company, Executives with accounting fraud:

https://www.sec.gov/litigation/litreleases/2017/lr23978.htm

[stocktrademan]

OSIR bullish 2.80









normal chart




log chart

[Renee]

OSIR delisted from the Nasdaq to the OTC:

http://otce.finra.org/DLAdditions

[willlbone]

Delisting from NASDAQ

[spsiege]

http://www.businesswire.com/news/home/20161215006156/en/Whistleblowers-Claim-MiMedx-Group-Defrauded-Investors-Lawsuit

[3ch0]

Staying on NASDAQ :) $OSIR

[3ch0]

Nice news. $OSIR

[3ch0]

Interesting week ahead. $OSIR

[3ch0]

I do not draw confidence nor base any trade in any market/exchange off those sources. Its not behove Imo.

[3ch0]

Consolidation $OSIR

[Randle Clint]

Found on the StockTwits board, "Osiris Therapeutics: Regenerative Technologies And Restated Financials seekingalpha.com/article/40... $OSIR Dump is coming, sell before the dump! Bearish".

Article showing a lot of current issues, including active investigations? and concerns about financial statements...

[3ch0]

Fantastic moves $OSIR

[Randle Clint]

New to this board, and wondering who can point to good DD for their recovery plan after disclosures this year. Thanks!

[ClayTrader]

* * $OSIR Video Chart 11-08-16 * *

Link to Video - click here to watch the technical chart video

[3ch0]

Settled higher base. OSIR

[3ch0]

Volatility has brought opportunity. Green trend still Long , We will see. OSIR

[3ch0]

Not the confidence building move.

[spsiege]

Well, Sept 12 has come and in a few hours went. Now what?

[3ch0]

Almost time for update as well.

[3ch0]

Yes, a good idea. Wonderful setup these past 3 months no ?
A close above 5.60 at the least

[spsiege]

Any idea what might happen Monday?

[3ch0]

Superior Day Osiris! Strong Green Trend Confirmation. $OSIR

[3ch0]

A line of research I have been particularly interested in/following will be very fruitful soon as it is Understood. OSIR

[3ch0]

The Potential for Osiris is Great.
Like the research and product applications.
Impacts many Lives Positively. Room for Growth.
Followed a long Time , Undervalued Greatly but unfortunate with last year but left a wide door for Opportunity.
The Trend is Green , Confidence Stronger

$OSIR

[BananaApes]

Osiris Therapeutics Profiled

Stem Cells Market About Therapeutic Benefits Boosts Value of US$119.5 bn in 2018

September 1st, 2016
http://www.medgadget.com/2016/09/stem-cells-market-about-therapeutic-benefits-boosts-value-of-us119-5-bn-in-2018.html

Global Stem Cells Market to Reach US $119.5 Bn by 2018, Rising Awareness About Therapeutic Benefits Boosts Popularity

Published: August 19th, 2016
http://www.sbwire.com/press-releases/stem-cells-market/release-716200.htm?utm_source=djournal&utm_medium=feed&utm_campaign=distribution

Also, "Some of the key enterprises operating in the global stem cells market, namely,...have been profiled in this study."

U.S. Stem Cell / BioHeart Profiled
Symbol: USRM
Shares Outstanding: 14.45M
Float: 12.17M
Stock Price: $0.02

A diamond in the rough or a 100 pound gold nugget?

[3ch0]

Looking good. OSIR

[3ch0]

Looking slick but long term trend still Green.

[3ch0]

Are we Breaking Uptrend OSIR?

[3ch0]

Trend Continues.
Strong Green Close Tomorrow
Starting to prime. $OSIR

[3ch0]

Looking good for tommrow. OSIR

[3ch0]

Nice pull - Confidence Building

[3ch0]

Nice Day , Like what I see
Trend Observed

[JefftDecker]

OSIR


where to next? maybe slight pullback to accumulate?

R5

[JefftDecker]

OSIR


where to next? maybe slight pullback to accumulate?

R5

[JefftDecker]

OSIR

running under the radar screen im guessing.

R5

[JefftDecker]

OSIR

hate gaps up but whatta we gonna do, didnt get as many as i wanted
but happy for now.

Happy Coding
R5

[spsiege]

August 4 2016
Grafix(R) Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex Wounds with Exposed Tendon and Bone Clinical Trial is Available Electronically in Peer-Reviewed Journal

COLUMBIA, Md. , Aug. 04, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that the manuscript from its multicenter prospective post-market clinical trial using Grafix was accepted for publication in the International Wound Journal , is now available online and will appear in an upcoming issue of the journal.
About the Trial (Protocol 310)
Patients between 18 and 85 years of age with confirmed type 1 or type 2 diabetes and with chronic complex diabetic foot wounds that extended through the dermis and into the subcutaneous tissue with evidence of exposed muscle, tendon, bone, and/or joint capsule were considered for this study. Ulcers had to be able to accommodate up to three 5 cm x 5 cm pieces of Grafix. Patients were excluded from the trial if the ulcer had any evidence of active infection at screening. Patients received treatment with Grafix weekly for up to 16 weeks. The primary endpoint measured 100% granulation of wound by 16 weeks as determined by the investigator. Secondary endpoints included complete wound closure rates, time to 100% granulation, number of applications, and percent wound area reduction at 4 weeks, 8 weeks, 12 weeks, and 16 weeks. 31 patients were enrolled, and 27 completed the study. The patient group had significant co-morbidity, with over 80% having hypertension, over 60% being current or former smokers, 55% having heart disease and 45% having had a previous partial amputation. The mean wound area was 14.6 cm2 with mean duration of 7.5 months, and 67.7% of patients failed advanced wound therapies prior to Grafix. For patients completing the protocol, the primary endpoint, 100% wound granulation by week 16, was met by 96.3% of patients in a mean of 6.8 weeks. Complete wound closure occurred in 59.3% (mean 9.1 weeks). Osiris Therapeutics partnered with CPC Clinical Research , an Academic Clinical Research Organization (CRO), who was responsible for data management and pharmacovigilance services. The protocol was submitted to clinicaltrials.gov (Reference # NCT02260609).
About Grafix®

[JefftDecker]

OSIR- News

small trades after hours at $5.77 tomorrow should be interesting

R5

[JefftDecker]

OSIR

Osiris actually headed up to some important pivot points and resistance zones on strength, with about 17% of the float shorted and a short ratio of 32.29, this could turn into a short squeeze fast should it keep trickling up. I'll be watching the action and dabbling for a few more just in case, Ill be cautious where to set a trailing stop just in case, these algorithms are a bitch sometimes to figure out. more later. trade well

Happy coding
R5

[3ch0]

I agree. Have had eyes on OSIR for a while as well.

[JefftDecker]

OSIR


dead duck bounce

R5

[JefftDecker]

OSIR

been stalking this for sometime, starting to look ready to go up
started a small position and will build going up should that happen,
Biotechs seem to be staying strong for now.

R5